Mogrify Funding Round

10/2/2023

Venture Equity

$10,000,000

Series A

The company intends to use the funds for further advancement of its pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.

Private & Independent

Biopharmaceutical

Bio-Innovation Centre 25 Cambridge Science Park, Milton R
Cambridge, England, CB4 0FW
UK

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.